Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heterogeneous-Nuclear Ribonucleoprotein Group A-B | 3 | 2011 | 12 | 0.980 |
Why?
|
| Fibroblasts | 10 | 2011 | 272 | 0.700 |
Why?
|
| Hippocampus | 2 | 2019 | 561 | 0.620 |
Why?
|
| Biomedical Engineering | 1 | 2017 | 5 | 0.610 |
Why?
|
| Gene Expression Regulation | 4 | 2019 | 1015 | 0.520 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 803 | 0.510 |
Why?
|
| DNA, Mitochondrial | 3 | 2009 | 175 | 0.500 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2015 | 187 | 0.490 |
Why?
|
| Inflammation | 1 | 2019 | 618 | 0.480 |
Why?
|
| MAP Kinase Signaling System | 1 | 2015 | 169 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 182 | 0.450 |
Why?
|
| Cognition Disorders | 1 | 2015 | 233 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 269 | 0.450 |
Why?
|
| Oxidative Stress | 1 | 2019 | 938 | 0.440 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2011 | 95 | 0.440 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 494 | 0.420 |
Why?
|
| Cognition | 1 | 2015 | 398 | 0.400 |
Why?
|
| Melanoma | 2 | 2009 | 96 | 0.360 |
Why?
|
| DNA | 6 | 1995 | 574 | 0.350 |
Why?
|
| Gene Expression | 2 | 2011 | 674 | 0.330 |
Why?
|
| Cyclophosphamide | 2 | 2019 | 54 | 0.300 |
Why?
|
| DNA Damage | 4 | 2009 | 352 | 0.290 |
Why?
|
| Doxorubicin | 2 | 2019 | 84 | 0.290 |
Why?
|
| Gene Deletion | 3 | 2008 | 166 | 0.290 |
Why?
|
| Thymine | 3 | 1992 | 25 | 0.270 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 159 | 0.270 |
Why?
|
| Luteinization | 1 | 2002 | 2 | 0.220 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2002 | 11 | 0.220 |
Why?
|
| Ribonucleoproteins | 1 | 2002 | 29 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2002 | 31 | 0.210 |
Why?
|
| Fertilization in Vitro | 1 | 2002 | 54 | 0.210 |
Why?
|
| Granulosa Cells | 1 | 2002 | 42 | 0.210 |
Why?
|
| Aging | 2 | 2008 | 664 | 0.210 |
Why?
|
| Phosphoranes | 1 | 2021 | 3 | 0.200 |
Why?
|
| Rubidium | 1 | 2021 | 6 | 0.200 |
Why?
|
| Imines | 1 | 2021 | 10 | 0.200 |
Why?
|
| Simian virus 40 | 6 | 1997 | 47 | 0.200 |
Why?
|
| Coordination Complexes | 1 | 2021 | 28 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 6 | 3 | 1997 | 18 | 0.170 |
Why?
|
| Ruthenium | 1 | 2019 | 15 | 0.170 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 36 | 0.170 |
Why?
|
| Organometallic Compounds | 1 | 2019 | 73 | 0.160 |
Why?
|
| Kidney Neoplasms | 1 | 2019 | 68 | 0.160 |
Why?
|
| Chemokines | 1 | 2019 | 97 | 0.160 |
Why?
|
| Signal Transduction | 2 | 2019 | 1908 | 0.160 |
Why?
|
| Telomere | 2 | 1996 | 56 | 0.160 |
Why?
|
| Gold | 1 | 2019 | 136 | 0.150 |
Why?
|
| Phosphorylation | 2 | 2011 | 928 | 0.150 |
Why?
|
| Humans | 18 | 2021 | 37093 | 0.150 |
Why?
|
| Protein Binding | 2 | 2011 | 972 | 0.150 |
Why?
|
| Cell Line | 5 | 2009 | 1354 | 0.140 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 461 | 0.140 |
Why?
|
| Mentors | 1 | 2017 | 127 | 0.140 |
Why?
|
| RNA | 2 | 1995 | 241 | 0.130 |
Why?
|
| Apoptosis | 2 | 2009 | 1398 | 0.130 |
Why?
|
| Rats, Inbred SHR | 1 | 2015 | 32 | 0.130 |
Why?
|
| Schools | 1 | 2017 | 260 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 1996 | 172 | 0.130 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2015 | 61 | 0.130 |
Why?
|
| Female | 5 | 2019 | 20969 | 0.120 |
Why?
|
| Neuronal Plasticity | 1 | 2015 | 103 | 0.120 |
Why?
|
| Cell Cycle | 2 | 2021 | 326 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2019 | 1618 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 1995 | 146 | 0.120 |
Why?
|
| Behavior, Animal | 1 | 2015 | 314 | 0.110 |
Why?
|
| Animals | 4 | 2019 | 15081 | 0.110 |
Why?
|
| Cell Transformation, Viral | 3 | 1997 | 29 | 0.110 |
Why?
|
| Translocation, Genetic | 1 | 1992 | 42 | 0.100 |
Why?
|
| Students | 1 | 2017 | 519 | 0.100 |
Why?
|
| Age Factors | 1 | 2015 | 1033 | 0.100 |
Why?
|
| Eukaryotic Initiation Factor-4E | 1 | 2011 | 15 | 0.100 |
Why?
|
| Aniline Compounds | 1 | 2011 | 23 | 0.100 |
Why?
|
| Melanins | 1 | 1992 | 36 | 0.100 |
Why?
|
| Purines | 1 | 2011 | 38 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 1995 | 539 | 0.100 |
Why?
|
| Multiprotein Complexes | 1 | 2011 | 54 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2015 | 517 | 0.100 |
Why?
|
| Protein Transport | 1 | 2011 | 302 | 0.090 |
Why?
|
| Cells, Cultured | 2 | 2011 | 1518 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2002 | 1207 | 0.090 |
Why?
|
| Sunlight | 1 | 2009 | 47 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2009 | 122 | 0.080 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 88 | 0.080 |
Why?
|
| Rats | 1 | 2015 | 3483 | 0.080 |
Why?
|
| Linear Models | 1 | 2008 | 275 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 623 | 0.070 |
Why?
|
| Phenotype | 1 | 2008 | 689 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2021 | 1198 | 0.060 |
Why?
|
| Bone Marrow | 2 | 1995 | 37 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 2231 | 0.060 |
Why?
|
| Transfection | 2 | 2002 | 523 | 0.060 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2002 | 13 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 77 | 0.050 |
Why?
|
| Hydrolases | 1 | 2002 | 15 | 0.050 |
Why?
|
| Glucuronidase | 1 | 2002 | 15 | 0.050 |
Why?
|
| Okadaic Acid | 1 | 2002 | 15 | 0.050 |
Why?
|
| alpha-Galactosidase | 1 | 2002 | 4 | 0.050 |
Why?
|
| Acid Phosphatase | 1 | 2002 | 21 | 0.050 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 35 | 0.050 |
Why?
|
| Molecular Sequence Data | 5 | 1997 | 1568 | 0.050 |
Why?
|
| Ceramides | 1 | 2002 | 42 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 252 | 0.050 |
Why?
|
| Aged, 80 and over | 1 | 2008 | 2379 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 295 | 0.050 |
Why?
|
| Lysosomes | 1 | 2002 | 91 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 113 | 0.050 |
Why?
|
| Base Sequence | 4 | 1996 | 997 | 0.050 |
Why?
|
| Cell Death | 1 | 2021 | 267 | 0.050 |
Why?
|
| Cell Cycle Proteins | 1 | 2002 | 229 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 409 | 0.040 |
Why?
|
| Cell Line, Transformed | 3 | 1997 | 91 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 356 | 0.040 |
Why?
|
| Adult | 2 | 2008 | 11712 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2021 | 492 | 0.040 |
Why?
|
| Angiogenic Proteins | 1 | 2019 | 7 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 807 | 0.040 |
Why?
|
| Chromosome Mapping | 2 | 1997 | 188 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 1039 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 259 | 0.040 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 1995 | 52 | 0.040 |
Why?
|
| Cell Movement | 1 | 2021 | 571 | 0.040 |
Why?
|
| Adolescent | 1 | 2008 | 5363 | 0.040 |
Why?
|
| Escherichia coli | 2 | 1989 | 453 | 0.030 |
Why?
|
| Karyotyping | 2 | 1994 | 47 | 0.030 |
Why?
|
| Aged | 1 | 2008 | 6741 | 0.030 |
Why?
|
| Cell Survival | 1 | 2019 | 864 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1995 | 111 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 1369 | 0.030 |
Why?
|
| Male | 2 | 2019 | 20025 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 1993 | 26 | 0.030 |
Why?
|
| Middle Aged | 1 | 2008 | 10129 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 1993 | 70 | 0.030 |
Why?
|
| Osmium Tetroxide | 2 | 1990 | 3 | 0.030 |
Why?
|
| Blotting, Western | 1 | 1995 | 859 | 0.030 |
Why?
|
| Chromosome Banding | 1 | 1992 | 6 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1992 | 69 | 0.030 |
Why?
|
| DNA Probes | 1 | 1992 | 29 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 1992 | 37 | 0.030 |
Why?
|
| Free Radicals | 1 | 1992 | 74 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1992 | 150 | 0.030 |
Why?
|
| Cross Reactions | 1 | 1992 | 83 | 0.030 |
Why?
|
| Antibodies | 1 | 1992 | 141 | 0.030 |
Why?
|
| Cell Division | 1 | 1992 | 307 | 0.020 |
Why?
|
| Thymine Nucleotides | 1 | 1990 | 3 | 0.020 |
Why?
|
| Mice | 2 | 2019 | 5913 | 0.020 |
Why?
|
| Nucleic Acid Denaturation | 1 | 1989 | 9 | 0.020 |
Why?
|
| Immunochemistry | 1 | 1989 | 9 | 0.020 |
Why?
|
| Bacteriophage phi X 174 | 1 | 1989 | 11 | 0.020 |
Why?
|
| Antibody Specificity | 1 | 1989 | 79 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1990 | 290 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2009 | 66 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 1989 | 186 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1989 | 431 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1989 | 448 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1989 | 304 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 730 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 626 | 0.020 |
Why?
|
| Antigens, Polyomavirus Transforming | 2 | 1996 | 13 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1997 | 53 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1996 | 22 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1997 | 142 | 0.010 |
Why?
|
| Telomerase | 1 | 1996 | 44 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 63 | 0.010 |
Why?
|
| Hybrid Cells | 1 | 1994 | 20 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 1994 | 47 | 0.010 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 1993 | 18 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 286 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 1996 | 213 | 0.010 |
Why?
|
| Luciferases | 1 | 1993 | 63 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 448 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 515 | 0.010 |
Why?
|